Zydus Lifesciences Limited reported a strong performance for the quarter ended December 31, 2024, with key financial metrics reflecting robust growth. The company’s consolidated revenue from operations reached ₹5,269.1 crore in Q3 FY25, marking a 16.78% increase from ₹4,505.2 crore in the corresponding quarter of the previous year.
Total expenses for the quarter came in at ₹4,142.5 crore, reflecting a 14.52% rise from ₹3,617.4 crore in Q3 FY24, driven by higher operational costs and increased input expenses.
Profit before tax (PBT) saw a significant jump of 46.78% year-on-year, reaching ₹1,044.6 crore compared to ₹711.7 crore in the same quarter last year. This growth was fueled by the company’s strategic focus on operational efficiency and optimized cost management.
Net profit from continuing operations registered a notable 29.6% YoY increase to ₹1,023.8 crore, up from ₹789.6 crore in Q3 FY24. The overall net profit, including exceptional items, stood at ₹1,023.5 crore, marking a 33.30% rise compared to ₹767.8 crore in the year-ago period.
The company posted a significant forex gain of ₹183 crore in Q3 FY25, compared to a gain of ₹21 crore in the same period last year, reflecting a substantial improvement in currency management and global trade execution. EBITDA surged 25.85% year-on-year to ₹1,387 crore compared to ₹1,102 crore in Q3 FY24. The EBITDA margin expanded to 26.3% from 24.5% YoY, driven by an improved product mix and effective cost optimization.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information.
